Tag
This review synthesizes phase 3 RAPIDe-3 trial results demonstrating oral deucrictibant’s rapid efficacy and safety for hereditary angioedema attacks, contextualized with phase 2 studies and prophylactic applications, highlighting its
This phase 2b trial demonstrates that oral icotrokinra, targeting the interleukin-23 receptor, significantly improves clinical outcomes in moderate to severe ulcerative colitis compared to placebo.
Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula
Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient managemen
EMA endorses sebetralstat, the first oral on-demand therapy for hereditary angioedema, following positive results from the KONFIDENT phase 3 trial, offering a more convenient and rapid treatment option for acute attacks.
